These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 1359828)

  • 1. [Do calcium inhibitors have any role in secondary prevention of myocardial infarction?].
    Vacheron A; Tabone X
    Ann Cardiol Angeiol (Paris); 1992 Jun; 41(6):343-7. PubMed ID: 1359828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Calcium inhibitors and post-infarction].
    Vacheron A
    Ann Cardiol Angeiol (Paris); 1996 Oct; 45(8):465-7. PubMed ID: 8952740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative relationship between resting heart rate reduction and magnitude of clinical benefits in post-myocardial infarction: a meta-regression of randomized clinical trials.
    Cucherat M
    Eur Heart J; 2007 Dec; 28(24):3012-9. PubMed ID: 17981830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Calcium antagonists in the secondary prevention of myocardial infarction].
    Lièvre M; Nony P
    Therapie; 1993; 48 Spec No():677-83. PubMed ID: 8091354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current status of calcium channel-blocking drugs after Q wave and non-Q wave myocardial infarction.
    Gibson RS
    Circulation; 1989 Dec; 80(6 Suppl):IV107-19. PubMed ID: 2574639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PROTECT (Prospective Reinfarction Outcomes in the Thrombolytic Era Cardizem CD Trial): a randomized, double-blind clinical trial of diltiazem versus atenolol in secondary prophylaxis post non-Q wave myocardial infarction.
    Goodman S; Hill C; Bata I; Fung A; Higginson L; Lam J; Massel D; McCans J; Nasmith J; Stanton E; Thompson C; Warnica W; Langer A
    Can J Cardiol; 1996 Nov; 12(11):1183-90. PubMed ID: 9191511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary and secondary prevention of myocardial infarction and strokes: an update of randomly allocated, controlled trials.
    Yusuf S; Lessem J; Jha P; Lonn E
    J Hypertens Suppl; 1993 Jun; 11(4):S61-73. PubMed ID: 8104243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medical prophylaxis for the post myocardial infarct patient.
    Cohen LS
    Cardiol Clin; 1988 Feb; 6(1):173-8. PubMed ID: 2901909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beta-blocker underuse in secondary prevention of myocardial infarction.
    Everly MJ; Heaton PC; Cluxton RJ
    Ann Pharmacother; 2004 Feb; 38(2):286-93. PubMed ID: 14742768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Which anti-ischemic treatment can be prescribed during and after the acute phase of myocardial infarction?].
    Delahaye F; Genoud JL; Colin C; Landrivon G; Ecochard R; Desseigne P; Pinzani A; André-Fouët X; Delaye J
    Arch Mal Coeur Vaiss; 1992 Nov; 85(11):1567-74. PubMed ID: 1363772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secondary prevention with calcium channel-blocking drugs in patients after myocardial infarction: a critical review.
    Moss AJ
    Circulation; 1987 Jun; 75(6 Pt 2):V148-53. PubMed ID: 3552311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Congestive heart failure and ischaemic heart disease treated with trandolapril and verapamil. DAVIT Study Group. Danish Verapamil Infarction Trial.
    Hansen JF
    J Hypertens Suppl; 1998 Jan; 16(1):S71-4. PubMed ID: 9534101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an INternational VErapamil SR-Trandolapril (INVEST) substudy.
    Bangalore S; Messerli FH; Cohen JD; Bacher PH; Sleight P; Mancia G; Kowey P; Zhou Q; Champion A; Pepine CJ;
    Am Heart J; 2008 Aug; 156(2):241-7. PubMed ID: 18657652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strategies for managing the patient with acute non-Q-wave myocardial infarction.
    Boden WE
    Clin Cardiol; 1989 Jul; 12(7 Suppl 3):III33-40. PubMed ID: 2575020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of calcium antagonists in progression of arteriosclerosis. Evidence from animal experiments and clinical experience. Part II. Clinical experience with preventive effects of calcium channel blockers in atheromatous coronary artery disease.
    Just H; Frey M
    Basic Res Cardiol; 1994; 89 Suppl 1():177-84. PubMed ID: 7945172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Therapeutic measures following acute myocardial infarct: differential use of PTCA, surgery and drugs].
    Noll G; Kaufmann U; Wenzel RR; Lüscher TF
    Schweiz Med Wochenschr; 1996 Feb; 126(5):164-76. PubMed ID: 8685687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Calcium antagonists after acute myocardial infarction.
    Ferrario M; Specchia G
    J Cardiovasc Pharmacol; 1989; 14 Suppl 9():S75-8. PubMed ID: 2483238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Beta-blockers or calcium channel blockers after myocardial infarction?].
    Helin M
    Duodecim; 1990; 106(1):122-32. PubMed ID: 1968376
    [No Abstract]   [Full Text] [Related]  

  • 19. Calcium antagonists in myocardial infarction.
    Zannad F; Sadoul N
    J Cardiovasc Pharmacol; 1990; 16 Suppl 1():S16-9. PubMed ID: 1706009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The treatment of ischemia in acute myocardial infarction].
    Kiowski W
    Schweiz Med Wochenschr; 1990 Oct; 120(42):1531-8. PubMed ID: 1978408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.